Verrica Pharmaceuticals Azioni (NASDAQ: VRCA)

Ultime notizie per Verrica Pharmaceuticals (NASDAQ:VRCA) Azioni

Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.

Verrica Pharmaceuticals Inc. - Common Stock

Verrica Pharmaceuticals Inc

UBS analyst Seth Gilbert maintains Open Text (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OTEX#NASDAQ">OTEX</a>) with a Neutral and lowers the price target from $32 to $28.

News

Price Target

Analyst Ratings

OTEX

UBS Maintains Neutral on Open Text, Lowers Price Target to $28

Marsh &amp; McLennan Cos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MMC#NYSE">MMC</a>) has outperformed the market over the past 20 years by 6.5% on an annualized basis producing an average annual return of 14.72%. Currently, Marsh &amp; McLennan Cos has a market capitalization of $111.99 billion. 
Buying $1000 In MMC: If an investor had bought $1000 of MMC stock 20 years ago, it would be worth $15,188.11 today based on a price of $227.29 for MMC at the time of writing.
<h3>Marsh &amp; McLennan Cos's Performance Over Last 20 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746226815_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

$1000 Invested In Marsh & McLennan Cos 20 Years Ago Would Be Worth This Much Today

UBS analyst Peter Grom maintains Utz Brands (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UTZ#NYSE">UTZ</a>) with a Neutral and lowers the price target from $15 to $13.5.

UBS Maintains Neutral on Utz Brands, Lowers Price Target to $13.5

UBS analyst Peter Grom maintains Hershey (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HSY#NYSE">HSY</a>) with a Neutral and lowers the price target from $175 to $170.

UBS Maintains Neutral on Hershey, Lowers Price Target to $170

UBS analyst Joseph Spak maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Neutral and lowers the price target from $51 to $50.

UBS Maintains Neutral on General Motors, Lowers Price Target to $50

UBS analyst Taylor McGinnis maintains Freshworks (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRSH#NASDAQ">FRSH</a>) with a Buy and lowers the price target from $22 to $19.

FRSH

UBS Maintains Buy on Freshworks, Lowers Price Target to $19

UBS analyst Ashwani Verma maintains Cytokinetics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CYTK#NASDAQ">CYTK</a>) with a Neutral and lowers the price target from $47 to $41.

CYTK

UBS Maintains Neutral on Cytokinetics, Lowers Price Target to $41

UBS analyst Taylor McGinnis maintains Five9 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FIVN#NASDAQ">FIVN</a>) with a Buy and lowers the price target from $55 to $35.

FIVN

UBS Maintains Buy on Five9, Lowers Price Target to $35

UBS analyst Damian Karas maintains Cognex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CGNX#NASDAQ">CGNX</a>) with a Buy and lowers the price target from $56 to $53.

CGNX

UBS Maintains Buy on Cognex, Lowers Price Target to $53

UBS analyst Peter Grom maintains Church &amp; Dwight Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CHD#NYSE">CHD</a>) with a Neutral and lowers the price target from $110 to $102.

UBS Maintains Neutral on Church & Dwight Co, Lowers Price Target to $102

UBS analyst John Lovallo maintains Builders FirstSource (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BLDR#NYSE">BLDR</a>) with a Buy and lowers the price target from $180 to $163.

BLDR

UBS Maintains Buy on Builders FirstSource, Lowers Price Target to $163

UBS analyst Joshua Spector maintains Air Products &amp; Chemicals (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APD#NYSE">APD</a>) with a Buy and lowers the price target from $335 to $324.

UBS Maintains Buy on Air Products & Chemicals, Lowers Price Target to $324

UBS analyst Dan Leonard maintains Bio-Rad Laboratories (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BIO#NYSE">BIO</a>) with a Buy and lowers the price target from $355 to $310.

UBS Maintains Buy on Bio-Rad Laboratories, Lowers Price Target to $310

UBS analyst Trung Huynh maintains Amgen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>) with a Neutral and lowers the price target from $319 to $315.

AMGN

UBS Maintains Neutral on Amgen, Lowers Price Target to $315

Devon Energy (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DVN#NYSE">DVN</a>) has outperformed the market over the past 5 years by 8.33% on an annualized basis producing an average annual return of 22.97%. Currently, Devon Energy has a market capitalization of $20.23 billion. 
Buying $100 In DVN: If an investor had bought $100 of DVN stock 5 years ago, it would be worth $275.31 today based on a price of $31.44 for DVN at the time of writing.
<h3>Devon Energy's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1746225912_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Devon Energy 5 Years Ago Would Be Worth This Much Today

UBS analyst Esther Rajavelu maintains Alnylam Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALNY#NASDAQ">ALNY</a>) with a Buy and raises the price target from $331 to $349.

ALNY

UBS Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $349

UBS analyst Kevin Caliendo maintains Alignment Healthcare (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) with a Neutral and raises the price target from $16 to $17.

ALHC

UBS Maintains Neutral on Alignment Healthcare, Raises Price Target to $17

UBS analyst Joseph Spak maintains Aptiv (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/APTV#NYSE">APTV</a>) with a Neutral and raises the price target from $58 to $66.

APTV

UBS Maintains Neutral on Aptiv, Raises Price Target to $66

UBS analyst Gavin Parsons maintains Howmet Aerospace (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) with a Neutral and raises the price target from $120 to $155.

UBS Maintains Neutral on Howmet Aerospace, Raises Price Target to $155

UBS analyst Karl Chalabala maintains Amicus Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FOLD#NASDAQ">FOLD</a>) with a Buy and raises the price target from $21 to $22.

FOLD

UBS Maintains Buy on Amicus Therapeutics, Raises Price Target to $22

Press Releases

Verrica Provides Business and Operational Update

Health Care

Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Comments

Verrica Pharmaceuticals

Notizie

Ultime notizie per Verrica Pharmaceuticals (NASDAQ:VRCA) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO